Controlled administration of chemodenervating pharmaceuticals

• US 5,298,019 A
• Filed: 01/13/1993
• Issued: 03/29/1994
• Est. Priority Date: 08/21/1990
• Status: Expired due to Term

• Current Assignee: Revance Therapeutics, Inc.
• Original Assignee: Associated Synapse Biologics
• Inventors: Borodic, Gary E.
• Primary Examiner(s): Millin, Vincent
• Assistant Examiner(s): Passaniti, Sebastiano
• Application Number:
  US08/004,090
• Time in Patent Office: 440 Days
• Field of Search: 604/49-53, 604/28, 128/749, 128/898, 128/632, 128/635, 128/DIG. 13, 514/903
• US Class Current: 604/511
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61K 8/99 from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention relates to a method for controlled administration of chemodernervating agents such as botulinum toxin-derived pharmaceutical, useful in attenuating neural stimulation and spasmodic activity of muscle. The method involves administration of novel dosage forms based upon the standardization of denervating pharmaceuticals. The invention also relates to novel methods of administrating chemodernervating agents in a controlled and reproducible manner so as to confine their effects to a given region of muscle mass while minimizing in adjacent muscle tissue.

Claims

1. A method of preserving teeth in vivo by decreasing spasm of involuntary contraction in a muscle or group of muscles of a patient induced by pathologic neutral stimulation caused by involuntary jaw clenching, the method comprising:

providing a chemodenervating pharmaceutical characterized in that a unit quantity of said pharmaceutical has been determined to denervate a predetermined volume of said muscle or said group of muscles;

determining a dose of said pharmaceutical required to denervate the predetermined volume of muscle without inducing significant paresis in muscle tissue adjacent said predetermined volume; and

injecting a chemodenervating preparation into at least one of the muscles selected from the group consisting of the masseter, temporalis, and pterygoid in an amount sufficient to diminish involuntary jaw clenching while permitting voluntary muscle stimulation, thereby retarding premature tooth wear.

3. The method of claim 1 or 2 wherein said denervating preparation comprises a neurotoxin derived from Clostridium botulinum.

2. A method of decreasing spasm or involuntary contraction in a muscle or group of muscles of a patient induced by pathologic neural stimulation caused by cerebrospinal injury or stroke, the method comprising:

providing a chemodenervating pharmaceutical characterized in that a unit quantity of said pharmaceutical has been determined to denervate a predetermined volume of said muscle or group of muscles;

determining a dose of said pharmaceutical required to denervate the predetermined volume of muscle without inducing significant paresis in muscle tissue adjacent said predetermined volume; and

injecting directly into said muscle or muscle group of said patient said dose of said pharmaceutical thereby to decrease the spasm or involuntary contraction in said muscle or muscle group while permitting voluntary muscle stimulation.